Concepedia

Z. Ren

ZR

Statistics

Publications

3

Citations

317

H-Index

3

Active since

2022

Affiliations

Zhongshan Hospital(Current)

Fudan University

University of California, Los Angeles

National Taiwan University Hospital

Nanjing University of Chinese Medicine

Z. Ren is an author at Zhongshan Hospital specializing in hepatology, oncology, and cancer therapeutics.

Top concepts

MedicineOncologyPathologyHepatologyPharmacologyCancer TherapyHepatocellular CarcinomaRadiation Oncology

Publications per year

2022–2024

3

Publications

3

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R.S. Finn, Masatoshi Kudo, Philippe Merle et al. · Annals of Oncology · 2022 · 192 citations

Hepatology, Lba34 Primary Results, Medicine +9

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin, L.S. Chan, Shanzhi Gu et al. · Annals of Oncology · 2022 · 97 citations

Lba35 Camrelizumab, First-line Therapy, Oncology +9

LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study

J. Llovet, R.S. Finn, Z. Ren et al. · Annals of Oncology · 2024 · 28 citations · Full text

Lba3 Transarterial Chemoembolization, Oncology, Hepatology +7

1–3 of 3